Calidi Biotherapeutics, Inc.
CLDI · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $7,459 | $7,941 | $15,265 | $9,169 |
| - Cash | $10,375 | $5,279 | $10,561 | $9,591 |
| + Debt | $3,113 | $4,011 | $4,705 | $7,036 |
| Enterprise Value | $197 | $6,673 | $9,409 | $6,614 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$427 | $0 | $0 | -$393 |
| % Margin | – | – | – | – |
| EBITDA | -$4,703 | -$5,298 | -$4,593 | -$3,577 |
| % Margin | – | – | – | – |
| Net Income | -$5,149 | -$5,715 | -$4,986 | -$4,097 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.21 | -1.99 | -2.21 | -3.22 |
| % Growth | -11.1% | 10% | 31.4% | – |
| Operating Cash Flow | -$4,238 | -$4,880 | -$7,131 | -$5,423 |
| Capital Expenditures | -$27 | -$57 | -$7 | -$5 |
| Free Cash Flow | -$4,265 | -$4,937 | -$7,138 | -$5,428 |